Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health and changes regularly. See the Directory of published versions

Example Bundle: ePI document Bundle for Lipcut Simvastatin 5 mg Tablet Package Leaflet for language en

Composition category: Raw
Composition status: final

Narrative Text


B. Package Leaflet

unavailable

Package leaflet: Information for the user

unavailable

What is in this leaflet

unavailable

1. What Lipcut Simvastatin 5 mg Tablet is and what it is used for

unavailable

2. What you need to know before you take Lipcut Simvastatin 5 mg Tablet

unavailable

3. How to take Lipcut Simvastatin 5 mg Tablet

unavailable

4. Possible side effects

unavailable

5. How to store Lipcut Simvastatin 5 mg Tablet

unavailable

6. Contents of the pack and other information

unavailable

Product Information

Lipcut Simvastatin 5 mg Tablet

PHPID: F92168108C432D63DACDD70444176BB3

Full name: Lipcut Simvastatin 5 mg Tablet

- Invented name part: Lipcut

- Scientific name part: Simvastatin

- Strength part: 5 mg

- Pharmaceutical dose form part: tablet

Name usage: English (Finland)

Authorised dose form:

Legal status of supply: Medicinal product subject to medical prescription

Domain: Human use

Resource status: active

Product classification:

Marketing Authorisation 1 of 1

Authorisation number: fin-x

Region:

Marketing authorisation holder: Sandoz A/S

Identifier:

  • ORG-100000848

Status: Active (2015-02-07T13:28:17Z)

Package 1 of 1

PMSWI: fin-x

Description:

Marketing status:

Pack size:

  • 5

    Package: 1 Box (Cardboard)

    Containing:

    Package: 28 Blister (PolyVinyl Chloride)

    Containing:

    Manufactured Item

    Dose form: Tablet

    Unit of presentation: Tablet

    Ingredient

    Role: Excipient

    Substance: TITANIUM DIOXIDE

    Ingredient

    Role: Excipient

    Substance: HYPROMELLOSE, UNSPECIFIED

    Ingredient

    Role: Active

    Substance: SIMVASTATIN

    Administrable Product (1 of 1)

    Dose form: Tablet

    Unit of presentation: Tablet

    Route of administration:

    • Oral use

    Ingredients:

    Ingredient

    Role: Excipient

    Substance: TITANIUM DIOXIDE

    Ingredient

    Role: Excipient

    Substance: HYPROMELLOSE, UNSPECIFIED

    Ingredient

    Role: Active

    Substance: SIMVASTATIN